A phase 3 open-label extension study of the efficacy and safety of lanadelumab for the prevention of angioedema attacks in patients with hereditary angioedema: trial design

被引：0
|
作者：
Riedl, M. [1 ]
Bernstein, J. A. [2 ]
Craig, T. [3 ]
Banerji, A. [4 ]
Magerl, M. [5 ]
Cicardi, M. [6 ,7 ]
Longhurst, H. J. [8 ]
Shennak, M. [9 ]
Yang, W. [10 ]
Schranz, J. [11 ]
Baptista, J. [11 ]
Busse, P. [12 ]
机构：
[1] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA
[2] Univ Cincinnati, Coll Med, Dept Internal Med, Allergy Sect Cincinnati, Cincinnati, OH USA
[3] Penn State Hershey Allergy Asthma & Immunol, Dept Med & Pediat, Hershey, PA USA
[4] Harvard Med Sch, Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Dept Med, Boston, MA USA
[5] Charite Univ Med Berlin, Dept Dermatol & Allergy, Berlin, Germany
[6] Univ Milan, Dept Biomed & Clin Sci, Milan, Italy
[7] Luigi Sacco Hosp Milan, Milan, Italy
[8] Barts Hlth NHS Trust, Dept Immunol, London, England
[9] Triumpharma Inc, Amman, Jordan
[10] Univ Ottawa, Med Sch, Ottawa Allergy Res Corp, Ottawa, ON, Canada
[11] Shire, Lexington, MA USA
[12] Icahn Sch Med Mt Sinai, Dept Med, Div Clin Immunol & Allergy, New York, NY 10029 USA
来源：
ALLERGY | 2017年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
1059
引用
收藏
页码：598 / 599
页数：2
相关论文
共 50 条
  • [1] An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension
    Riedl, Marc A.
    Bernstein, Jonathan A.
    Craig, Timothy
    Banerji, Aleena
    Magerl, Markus
    Cicardi, Marco
    Longhurst, Hilary J.
    Shennak, Mustafa M.
    Yang, William H.
    Schranz, Jennifer
    Baptista, Jovanna
    Busse, Paula J.
    [J]. CLINICAL AND TRANSLATIONAL ALLERGY, 2017, 7
  • [2] Efficacy and safety of lanadelumab in Japanese patients with hereditary angioedema: A phase 3 multicenter, open-label study
    Hide, Michihiro
    Ohsawa, Isao
    Nurse, Christina
    Yu, Ming
    [J]. JOURNAL OF DERMATOLOGY, 2023, 50 (11): : 1381 - 1391
  • [3] An open-label, multicentre phase 3 study evaluating lanadelumab for the prevention of hereditary angioedema attacks in paediatric patients: SPRING study design
    Farkas, H.
    Lumry, W. R.
    Li, H. H.
    Tachdjian, R.
    Aygoren-Pursun, E.
    Lu, P.
    Nurse, C.
    Pedrosa, M.
    [J]. ALLERGY, 2020, 75 : 467 - 468
  • [4] Garadacimab for hereditary angioedema prophylaxis: Efficacy and safety from a Phase 2 open-label extension trial
    Craig, T. J.
    Reshef, A.
    Lumry, W. R.
    Saguer, I. Martinez
    Jacobs, J. S.
    Yang, W. H.
    Aygoren-Pursun, E.
    Keith, P. K.
    Busse, P.
    Magerl, M.
    Feuersenger, H.
    Bica, M. A.
    Glassman, F.
    Pragst, I.
    Levy, D. S.
    [J]. ALLERGOLOGIE, 2023, 46 (08) : 560 - 561
  • [5] Icatibant for the treatment of repeated attacks of hereditary angioedema: FAST-3 trial open-label extension study phase
    Lumry, W.
    Levy, R.
    Li, H.
    Farkas, H.
    [J]. ALLERGY, 2013, 68 : 254 - 255
  • [6] Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: Open-label continuation study
    Lumry, William R.
    Bernstein, Jonathan A.
    Li, H. Henry
    MacGinnitie, Andrew J.
    Riedl, Marc
    Soteres, Daniel F.
    Craig, Timothy J.
    Campion, Marilyn
    Iarrobino, Ryan
    Stolz, Leslie E.
    Pullman, William E.
    [J]. ALLERGY AND ASTHMA PROCEEDINGS, 2013, 34 (02) : 155 - 161
  • [7] LANADELUMAB FOR PREVENTION OF ATTACKS IN HEREDITARY ANGIOEDEMA: RESULTS FROM THE PHASE 3 HELP STUDY
    Banerji, A.
    Riedl, M.
    Bernstein, J.
    Cicardi, M.
    Longhurst, H.
    Zuraw, B.
    Maurer, M.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2017, 119 (05) : S5 - S5
  • [8] Lanadelumab for prevention of attacks in hereditary angioedema: results from the Phase 3 HELP Study
    Banerji, A.
    Riedl, M. A.
    Bernstein, J. A.
    Cicardi, M.
    Longhurst, H. J.
    Zuraw, B. L.
    Bruelle, J.
    Maurer, M.
    [J]. SWISS MEDICAL WEEKLY, 2018, 148 : 28S - 29S
  • [9] PHASE 2 OPEN-LABEL EXTENSION STUDY WITH DONIDALORSEN TREATMENT IN PATIENTS WITH HEREDITARY ANGIOEDEMA
    Bordone, L.
    Riedl, M.
    Newman, K.
    Lui, C.
    Alexander, V.
    Schneider, E.
    Cohn, D.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 129 : S33 - S33
  • [10] Long-term prevention of attacks with lanadelumab across subgroups of patients with hereditary angioedema (HAE): final results from the HELP open-label extension study
    Maurer, M.
    Bernstein, J. A.
    Jacobs, J.
    Lumry, W. R.
    Ren, H.
    Soteres, D.
    Yu, M.
    Martinez-Saguer, I
    [J]. ALLERGY, 2021, 76 : 10 - 10
12345